Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide
- First Online:
- Cite this article as:
- Matsuno, A., Murakami, M., Hoya, K. et al. Med Mol Morphol (2014) 47: 1. doi:10.1007/s00795-013-0050-z
- 374 Downloads
There have been several reports of temozolomide (TMZ) treatment of pituitary carcinomas and atypical adenomas. O6-methyl-guanine-DNA methyltransferase is not the sole molecule determining the sensitivity to TMZ in pituitary carcinomas and atypical adenomas. The Japan Society of Hypothalamic and Pituitary Tumors study suggests that MSH6, one of mismatch repair pathway enzyme, fulfills a contributory role to the efficacy of TMZ treatment for pituitary carcinomas and atypical adenomas. The preserved MSH6 function might be essential for the responsiveness to TMZ treatment in pituitary carcinomas and atypical adenomas.